

Johnathon E Liddicoat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1134668/publications.pdf>

Version: 2024-02-01

22
papers

114
citations

1306789

7
h-index

1372195

10
g-index

22
all docs

22
docs citations

22
times ranked

97
citing authors

#	ARTICLE	IF	CITATIONS
1	Precision medicine: drowning in a regulatory soup?. <i>Journal of Law and the Biosciences</i> , 2016, 3, 281-303.	0.8	18
2	After Myriad, what makes a gene patent claim 'markedly different' from nature?. <i>Nature Biotechnology</i> , 2017, 35, 820-825.	9.4	18
3	Myriad's impact on gene patents. <i>Nature Biotechnology</i> , 2016, 34, 1119-1123.	9.4	14
4	Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?. <i>Nature Biotechnology</i> , 2018, 36, 1146-1149.	9.4	11
5	How does emerging patent case law in the US and Europe affect precision medicine?. <i>Nature Biotechnology</i> , 2019, 37, 1118-1125.	9.4	11
6	Mayo's impact on patent applications related to biotechnology, diagnostics and personalized medicine. <i>Nature Biotechnology</i> , 2019, 37, 513-518.	9.4	10
7	Are the gene-patent storm clouds dissipating? A global snapshot. <i>Nature Biotechnology</i> , 2015, 33, 347-352.	9.4	9
8	Continental drift? Do European clinical genetic testing laboratories have a patent problem?. <i>European Journal of Human Genetics</i> , 2019, 27, 997-1007.	1.4	8
9	Mapping the European patent landscape for medical uses of known products. <i>Nature Biotechnology</i> , 2021, 39, 1336-1343.	9.4	3
10	Precision Medicine: Legal and Ethical Challenges. <i>SSRN Electronic Journal</i> , 2017, , .	0.4	2
11	One year after Vanda, are diagnostics patents transforming into methods of treatment to overcome Mayo-based rejections?. <i>Nature Biotechnology</i> , 2020, 38, 279-283.	9.4	2
12	An empirical study of large, human biobanks: intellectual property policies and financial conditions for access. <i>Journal of Law and the Biosciences</i> , 2021, 8, 1-18.	0.8	2
13	European patent protection for medical uses of known products and drug repurposing. <i>Nature Biotechnology</i> , 2022, 40, 465-471.	9.4	2
14	Standing on the Edge – What Type of “Exclusive Licensees” Should be Able to Initiate Patent Infringement Actions?. <i>IIC International Review of Intellectual Property and Competition Law</i> , 2017, 48, 626-651.	0.3	1
15	Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the “+1” Regulatory Exclusivity. <i>IIC International Review of Intellectual Property and Competition Law</i> , 2021, 52, 825-851.	0.3	1
16	Should We Change EU Law to Disallow DNA Patents?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
17	A Role for Virtual Biotechnology Companies in Drug Discovery and Development?. <i>Journal of Commercial Biotechnology</i> , 2013, 19, .	0.2	1
18	When can exclusive licensees initiate patent infringement proceedings? – Lessons for global IP licensing transactions – from two recent UK cases. <i>Journal of Intellectual Property Law and Practice</i> , 2019, 14, 2-4.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Reply to C.D. Richter. <i>European Journal of Human Genetics</i> , 2020, 28, 537-538.	1.4	0
20	Time to Get Serious about Privacy Policies: The Special Case of Genetic Privacy. <i>Federal Law Review</i> , 2014, 42, 1-32.	0.2	0
21	Time to Get Serious about Privacy Policies: The Special Case of Genetic Privacy. <i>Federal Law Review</i> , 2014, 42, 1-32.	0.2	0
22	Open Innovation with Large Bioresources: Goals, Challenges and Proposals. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0